StockData
BioVie Inc. logo

BioVie Inc. (BIVI) company profile

BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$0.91−0.03 (-3.50%)

Close on Nov 19, 2026Market cap $6.86MP/E –Yield –

About BioVie

Pharmaceutical Preparations, SIC 2834

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for neurological and neurodegenerative disorders as well as advanced liver disease. Its neurodegenerative pipeline centers on bezisterim (NE3107), an investigational, orally administered small molecule designed to inhibit neuroinflammation and insulin resistance in conditions such as Parkinson’s disease, Alzheimer’s disease, and long COVID. In liver disease, the company develops BIV201, a continuous infusion liquid formulation of terlipressin targeting ascites and complications of liver cirrhosis. Because its therapeutic candidates remain under clinical investigation, the company does not have commercial products or regular commercial customers.

The company operates in the United States and maintains intellectual property and clinical development activities across international jurisdictions, holding patents in countries such as the United States, Canada, Europe, China, Japan, Australia, Chile, and Mexico. BioVie Inc. maintains its principal executive offices in Carson City, Nevada.

Summary of the business section of BioVie's latest annual report, written by StockData.

Company profile

Company

Legal name
BioVie Inc.
Headquarters
Carson City, NV
Address
680 W Nye Lane, Suite 201 89703
Phone
(775) 888-3162
Employees
13, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
June 30
Auditor
EisnerAmper LLP, Iselin

Stock & identifiers

Ticker
BIVI
Other tickers
BIVIW
Exchange
Nasdaq
IPO date
Sep 18, 2020
Shares outstanding
8M, Aug 10, 2026
Public float
$8.45M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Jul 7, 2025; 1-for-10 reverse, Aug 6, 2024; 1-for-125 reverse, Feb 13, 2020
SEC CIK
1580149
CUSIP
09074F504
ISIN
US09074F5044
FIGI
BBG00548BTD6
Share class FIGI
BBG00548BTF4
EIN
46-2510769

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Cuong V. DoPresident & CEO, Director31,109
Joseph M. PalumboChief Medical Officer6,036
Joanne Wendy KimChief Financial Officer3,441
Amy Suzon ChappellDirector727
Sigmund RogichDirector36,926
Kameel D. FaragDirector–
James Paul LangDirector68,622
Michael Edward ShermanDirector20,679
Robert J. HaririDirector42,254
Richard J. BermanDirector40,643

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Cuong Do
Chief Executive Officer and President
$640.00K$96.00K$653.99K$1.39M+62%
Joanne Wendy Kim
Chief Financial Officer and Corporate Secretary
$350.00K$39.38K$108.23K$497.60K+18%
Joseph Palumbo
Chief Medical Officer
$580.00K$65.25K$129.76K$775.01K+16%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 18, 2020
Offer price
$10.00
Securities offered
1,565,200
Gross proceeds
$15.65M
Exchange
Nasdaq
Lock-up ends (est.)
Mar 17, 2021

“Per Share Total Initial public offering price $ 10.00 $ 15,652,000 Underwriting discounts and commissions (1) $ 0.70 $ 1,095,640 Proceeds to us, before expenses $ 9.30 $ 14,566,360 (1) We refer you to the “Underwriting” section of this prospectus beginning on page 50 for additional information regarding the underwr”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“Company has 13 employees which are all full time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?